about
Oncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future PerspectivesThe colorectal cancer immune microenvironment and approach to immunotherapies.Emulating Host-Microbiome Ecosystem of Human Gastrointestinal Tract in Vitro.Regulation of inflammation by microbiota interactions with the host.Inflammasomes and Cancer: The Dynamic Role of the Inflammasome in Tumor DevelopmentHow can computation advance microbiome research?Immune-related adverse events during anticancer immunotherapy: Pathogenesis and management.Leukotriene B4-receptor-1 mediated host response shapes gut microbiota and controls colon tumor progression.Adipose Tissue Metabolism and Cancer Progression: Novel Insights from Gut Microbiota?Strategies to Improve the Efficacy of Dendritic Cell-Based Immunotherapy for Melanoma.Adjuvant Probiotics and the Intestinal Microbiome: Enhancing Vaccines and Immunotherapy Outcomes.A Believer's Overview of Cancer Immunosurveillance and Immunotherapy.Natural Killer T Cells: An Ecological Evolutionary Developmental Biology Perspective.Mer Receptor Tyrosine Kinase Signaling Prevents Self-Ligand Sensing and Aberrant Selection in Germinal Centers.The gut microbiome, symptoms, and targeted interventions in children with cancer: a systematic review.Discovery and application of immune biomarkers for hematological malignancies.The gut virome: a neglected actor in colon cancer pathogenesis.Gut bacteria may control development of hepatocellular carcinoma.Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system.Widespread spontaneous hyperproliferation, melanosis and melanoma in Hgf-Cdk4R24C mice.Of Microbes and Minds: A Narrative Review on the Second Brain Aging.Analysis of microbial sequences in plasma cell-free DNA for early-onset breast cancer patients and healthy females.IL-1 and IL-1 regulatory pathways in cancer progression and therapy.Increased gut permeability in cancer cachexia: mechanisms and clinical relevance.Gut Microbiota: An Integral Moderator in Health and Disease.Pharmacomicrobiomics: exploiting the drug-microbiota interactions in anticancer therapies.Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges.Gut microbiome modulates efficacy of immune checkpoint inhibitors.Proteinaceous Secretory Metabolites of Probiotic Human Commensal Enterococcus hirae 20c, E. faecium 12a and L12b as Antiproliferative Agents Against Cancer Cell Lines.Organoids Provide an Important Window on Inflammation in Cancer.Large-scale database mining reveals hidden trends and future directions for cancer immunotherapy.Profiling the Urinary Microbiota in Male Patients With Bladder Cancer in China.Microbiota Composition and the Integration of Exogenous and Endogenous Signals in Reactive Nasal Inflammation.Shifts of Faecal Microbiota During Sporadic Colorectal Carcinogenesis.Immuno-Oncology: Emerging Targets and Combination TherapiesProbiotics and Their Potential Preventive and Therapeutic Role for Cancer, High Serum Cholesterol, and Allergic and HIV DiseasesOral hygiene might prevent cancerThe urinary microbiome associated with bladder cancerStudying cancer immunotherapy using patient-derived xenografts (PDXs) in humanized mice
P2860
Q33679505-AA22D382-878B-43EA-AE92-2DCC9CFB13A3Q38638847-930CCEC2-655D-41C4-AD27-09AB353A682BQ38685792-9763618E-FE2D-48F9-92D5-9C6142C64387Q39443984-0C3B78C2-9A86-4137-A1AC-D1CE7BE65B65Q41684112-2064935A-A593-4A86-BC39-56B241CE27A8Q42362020-4475924B-B484-4457-8C12-CBCA271F29B5Q45026631-7F73EA81-764C-45C1-9F49-4312A1416A15Q46376244-029FD013-4C2F-49E2-86BC-21D4DAA141A9Q47099645-E7B2E796-461C-49F6-8F30-EF06E5483E48Q47135720-63A130F2-B8CA-477D-B8CF-BF5375E9A9C3Q47159439-C97F3E41-7C94-4FB6-BF2F-07EF0841E917Q47195265-BD8439CB-F4A0-4FAA-99BC-9520222C306FQ47221129-26FB2813-9CEB-43D2-9C39-2626CBC2B8E4Q47423635-B41B6FB4-F77B-44A0-850F-BA92F11E8C2CQ47425267-7D0FBC74-CDA7-4417-A3B6-5032DDDD44A7Q47681393-DA0C3D3A-9E0E-4FFF-948A-8874B83F1E11Q47927527-5EAA8C1D-D26B-4660-9DE1-597865714118Q49183637-DFE1A062-B8C7-448A-928D-CF787464EC60Q50070316-BAF6A86C-036B-40D9-BFCD-D4DAAF05AD77Q50099450-4655D153-B1EB-4A98-B149-6BDF33C57366Q51733135-57300B57-A802-4CA9-986F-FEF021B63C93Q53080587-F1C8449C-C51A-4ABF-AAC0-C3F13286E350Q53179726-5BE845CC-6247-486F-AD21-D49691D9A842Q53688957-2B06D7C1-88E5-4136-AC45-A191D8853F00Q55029540-52EAD992-D652-47B9-9CCD-7AD318261B83Q55040688-C3CE4038-F92B-4701-BC33-06033269D049Q55190117-78EF59A3-550E-4852-B051-2AF25656EDF2Q55240704-434EC603-539A-4AD4-AEF3-64111642EC58Q55259937-74B51259-EF44-4471-9682-1D3840855387Q55302559-86C88DDE-CD1B-4727-B2D0-7B92701D5198Q55316070-ED68FB5A-DB02-4C62-BF3E-B7EAD72FB756Q55400961-339C97CE-762B-4031-9A25-6396EFC888C9Q55424073-7B7F711A-29D4-463B-9E6D-696BDBC30812Q55553797-265C878D-4622-4DC3-8DC7-68399C78DCA5Q56889817-1F8C9C01-182A-440C-9D64-0A0C9AF38CB0Q58693358-E37CCD3F-F86F-4A36-99B8-BDCF744FED34Q58700677-36809B77-1B5C-4DDD-BA16-9F35CC7D28EFQ58783075-C2D56481-2407-47CA-8C1F-26B5C5DC51E5Q58797496-F947D490-89E6-491E-A064-1FF43381B332
P2860
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Microbiota: a key orchestrator of cancer therapy.
@en
Microbiota: a key orchestrator of cancer therapy.
@nl
type
label
Microbiota: a key orchestrator of cancer therapy.
@en
Microbiota: a key orchestrator of cancer therapy.
@nl
prefLabel
Microbiota: a key orchestrator of cancer therapy.
@en
Microbiota: a key orchestrator of cancer therapy.
@nl
P2860
P356
P1476
Microbiota: a key orchestrator of cancer therapy
@en
P2093
Giorgio Trinchieri
P2860
P2888
P304
P356
10.1038/NRC.2017.13
P407
P50
P577
2017-03-17T00:00:00Z